ResearcherShanghai Jiao Tong UniversityActive in the last 2 years
Jiejie Qin
Matched on OpenAlex author ID A5078654882. Sources: OpenAlex.
Their work
- Papers
- 5 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 39
2023: 1 paper · 2024: 2 papers · 2025: 2 papers
Papers 5
- CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Co-author DOI 10.1016/j.canlet.2025.217898↗
- Prevalence and clinical relavance of germline mutations in Chinese patients with pancreatic cancer. Co-author DOI 10.1186/s12964-025-02281-1↗
- BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
- Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. First author DOI 10.1038/s41591-023-02790-x↗
- Identification of COL12A1 as a novel diagnostic marker in pancreatic ductal adenocarcinoma by global proteome analysis Co-author DOI 10.21203/rs.3.rs-3037921/v1↗
Closest collaborators
The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Lingxi Jiang · 4 shared papers, 2023–2025 · strength 0.78
- Paper CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. DOI 10.1016/j.canlet.2025.217898↗
- Paper Identification of COL12A1 as a novel diagnostic marker in pancreatic ductal adenocarcinoma by global proteome analysis DOI 10.21203/rs.3.rs-3037921/v1↗
- Paper BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. DOI 10.1002/advs.202306298↗
- Baiyong Shen · 4 shared papers, 2023–2025 · strength 0.78
- Paper CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. DOI 10.1016/j.canlet.2025.217898↗
- Paper Identification of COL12A1 as a novel diagnostic marker in pancreatic ductal adenocarcinoma by global proteome analysis DOI 10.21203/rs.3.rs-3037921/v1↗
- Paper BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. DOI 10.1002/advs.202306298↗
- Yizhi Cao · 2 shared papers, 2024–2025 · strength 0.41
- Yang Liu · 2 shared papers, 2024–2025 · strength 0.41
- Xiaomei Tang · 2 shared papers, 2024 · strength 0.28
- Yu Jiang · 1 shared paper, 2025 · strength 0.26
- Na Yao · 1 shared paper, 2025 · strength 0.26
- Baiyong Shen · 1 shared paper, 2025 · strength 0.26
- Jiabin Jin · 1 shared paper, 2025 · strength 0.26
- Lijie Han · 1 shared paper, 2024 · strength 0.15
- Shuyu Zhai · 1 shared paper, 2024 · strength 0.15
- Yihao Liu · 1 shared paper, 2024 · strength 0.15
- Weishen Wang · 1 shared paper, 2024 · strength 0.15
- Dongfeng Cheng · 1 shared paper, 2024 · strength 0.15
- Hao Chen · 1 shared paper, 2024 · strength 0.15
- Chenghong Peng · 1 shared paper, 2024 · strength 0.15
- Xiaxing Deng · 1 shared paper, 2024 · strength 0.15
- Youwei Zhu · 1 shared paper, 2024 · strength 0.15
- Chenlei Wen · 1 shared paper, 2024 · strength 0.15
- Yongsheng Jiang · 1 shared paper, 2024 · strength 0.15
- Meilin Xue · 1 shared paper, 2024 · strength 0.15
- Ronghao Zhang · 1 shared paper, 2024 · strength 0.15
- Pengyi Liu · 1 shared paper, 2024 · strength 0.15
- Jiaxin Luo · 1 shared paper, 2024 · strength 0.15
- Kailian Zheng · 1 shared paper, 2024 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.